摘要
失代偿期丙型病毒性肝炎(简称丙肝,hepatitis C)肝硬化是干扰素治疗的禁忌,其疾病进展快、预后差。直接抗病毒药物(direct-acting antiviral agents,DAAs)的出现是慢性丙肝抗病毒治疗的里程碑。DAAs治疗失代偿期丙肝肝硬化病毒学应答率高、安全性好,并可在一定程度上改善肝功能;但同时有多项注册研究及真实世界研究提出这部分患者的治疗亦面临诸多问题。本文对DAAs治疗失代偿期丙肝肝硬化的效果及存在的问题进行介绍。
Patients with decompensated cirrhosis, for whom pegylated interferon （PegIFN） is contraindicated, often have a rapid progression and poor prognosis. Direct-acting antiviral agents （DAAs） have changed the chronic hepatitis C （CHC） therapeutic scenario. For patients with decompensated cirrhosis, DAAs combinations in all oral regimens have led to overall high sustained virological response （SVR）, much more safety and improved liver function. However, registration trials and real-life data have also demonstrated several prob lems. We aimed to discuss the effectiveness and potential challenges in HCV treatment for patients with decompensated cirrhosis with oral DAAs.
作者
王艳
贾继东
WANG Yan;JIA Ji dong(Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China)
出处
《中国病毒病杂志》
CAS
2017年第6期408-411,共4页
Chinese Journal of Viral Diseases
关键词
直接抗病毒药物
肝炎病毒
丙型
丙型肝炎
失代偿期肝硬化
抗病毒治疗
Direct-acting antiviral agents （DAAs）
ttepatitis virus C
Hepatitis C
Decompensated cirrhosis
Antiviral therapy
